tiprankstipranks
Advertisement
Advertisement

LifeMD Posts Q1 Results, Reaffirms 2026 Profitability Outlook

Story Highlights
  • LifeMD’s Q1 2026 revenue beat guidance with stronger margins but a planned EBITDA loss.
  • Subscriber growth in GLP-1 and women’s health surged, supporting reaffirmed 2026 growth and profit targets.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
LifeMD Posts Q1 Results, Reaffirms 2026 Profitability Outlook

Meet Samuel – Your Personal Investing Prophet

LifeMD ( (LFMD) ) has issued an update.

LifeMD reported first-quarter 2026 results on May 6, 2026, with revenue of $50.2 million, slightly below the prior year but above guidance, and an adjusted EBITDA loss of $4.5 million in line with expectations, driven by elevated, front-loaded marketing spend. Gross margin expanded 420 basis points year over year to 88% on favorable product mix and lower fulfillment costs, while the company exited the quarter with $34.5 million in cash, no debt and an undrawn $30 million revolver.

Subscriber metrics underscored LifeMD’s growth strategy, as active telehealth subscribers rose 26% to about 365,000, including record GLP-1 weight management sign-ups and 657% quarter-over-quarter growth in women’s health patients alongside sharply lower acquisition costs. Management highlighted momentum across insurance-supported programs and reaffirmed 2026 guidance for $220 million to $230 million in revenue and positive full-year adjusted EBITDA, signaling confidence that recent investments in weight management and women’s health will translate into stronger profitability in the second half of the year.

The most recent analyst rating on (LFMD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.

Spark’s Take on LFMD Stock

According to Spark, TipRanks’ AI Analyst, LFMD is a Neutral.

The score is driven primarily by mixed financial performance (profitability inflection and strong gross margins, but revenue contraction, negative operating profit, and volatile cash flow). Earnings call guidance and operating momentum are supportive, while technicals show strong but potentially overextended near-term momentum and valuation remains weakened by negative earnings and no dividend support.

To see Spark’s full report on LFMD stock, click here.

More about LifeMD

LifeMD, Inc. is a U.S.-based provider of virtual primary care, offering telemedicine, lab access, pharmacy services and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management and hormone therapy. The company operates a vertically integrated digital care platform supported by a 50-state affiliated medical group, an affiliated pharmacy and a domestic patient care center, targeting accessible, affordable online healthcare.

Average Trading Volume: 1,221,054

Technical Sentiment Signal: Buy

Current Market Cap: $244.2M

For a thorough assessment of LFMD stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1